CN102924550A - Decitabine 5'-O-amino-acid ester prodrug and preparation method thereof - Google Patents
Decitabine 5'-O-amino-acid ester prodrug and preparation method thereof Download PDFInfo
- Publication number
- CN102924550A CN102924550A CN2012103857243A CN201210385724A CN102924550A CN 102924550 A CN102924550 A CN 102924550A CN 2012103857243 A CN2012103857243 A CN 2012103857243A CN 201210385724 A CN201210385724 A CN 201210385724A CN 102924550 A CN102924550 A CN 102924550A
- Authority
- CN
- China
- Prior art keywords
- decitabine
- amino acid
- carbobenzoxy
- cbz
- amino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Abstract
The invention belongs to the technical field of medicine, and discloses a decitabine 5'-O-amino-acid ester prodrug for treating myelodysplastic syndrome and a preparation method thereof. The decitabine is subjected to purposeful structure modification, so that the decitabine is combined with different amino acids, thereby designing and synthesizing the compound decitabine 5'-O-amino-acid ester prodrug disclosed as (I). In (I), R is an amino acid, preferably L-valine, D-valine, L-isoleucine, L-phenylalanine or L-tryptophane. Compared with oral decitabine, the invention obviously enhances the bioavailability of the prodrug, and is hopeful to develop a carrier prodrug with more definite curative effect for treating myelodysplastic syndrome.
Description
Technical field
The invention belongs to medical technical field, relate to Decitabine (5-azepine-2-deoxycytidine) prodrug and preparation method thereof, be specifically related to 5 '-O-amino acid ester prodrug of a kind of 5-azepine for the treatment of myelodysplastic syndrome-2-deoxycytidine and preparation method thereof.
Background technology
The Decitabine chemical name is 5-azepine-2-deoxycytidine.Decitabine is as special dna methylation transferase inhibitor, by the deoxycytidine kinase phosphorylation, and with phosphatic form and DNA fusion, the process that methylates of reversible DNA, inducing tumor cell is to normal cell differentiation or inducing apoptosis of tumour cell.Commodity were called Dacogen to Decitabine in U.S.'s approval listing in 2006.But Decitabine polarity is large, and the small intestine membrane permeability is poor, and causing its oral administration biaavailability only is 3.9% ~ 14%.Therefore be necessary to seek the membrane permeability that a kind of approach improves Decitabine, and then improve its oral administration biaavailability.According to a large amount of bibliographical informations, if the free hydroxyl of nucleoside medicine is modified, may improve membrane permeability and the oral administration biaavailability of this class medicine.
Summary of the invention
The object of the present invention is to provide 5 '-O-amino acid ester prodrug of a kind of 5-azepine-2-deoxycytidine, namely 5 ' of Decitabine-O-amino acid esters prodrug and preparation method thereof.
5 ' of described Decitabine-O-amino acid esters prodrug general structure is:
Wherein R is amino-acid residue, and described amino-acid residue is selected from Valine, D-Val, ILE, L-Phe or L-Trp.
Described Decitabine 5 '-O-amino acid ester comprises following compound:
Decitabine 5 ' of the present invention-O-amino acid esters prodrug prepares by the following method: the amino acid of Decitabine and protection is at dicyclohexylcarbodiimide and N; under the N-4-dimethyl aminopyridine catalytic condition; carry out esterification; then carry out catalytic hydrogenation and slough protecting group formation Decitabine 5 '-O-amino acid ester prodrug, reaction formula is as follows:
Wherein Y is the amino acid of carbobenzoxy-(Cbz) protection, and X is the residue of carbobenzoxy-(Cbz) protected amino acid, and R is amino-acid residue.The preferred N-benzyloxy-oxo-L-valine of Y, N-carbobenzoxy-(Cbz)-D-Val, N-carbobenzoxy-(Cbz)-ILE, N-carbobenzoxy-(Cbz)-L-Phe or N-carbobenzoxy-(Cbz)-L-Trp.
The concrete synthetic method of 5 ' of Decitabine-O-amino acid ester is carried out according to following general routes outlined:
The first step:
Under 0 ° of C condition, the acid of 50mmol N-benzyloxycarbonyl amino and 50mmol dicyclohexylcarbodiimide are mixed, stir 1h, drip gradually 11.8g (50mmol) Decitabine and 5mmol N with dropping funnel, the DMF of N-4-dimethyl aminopyridine (250ml) solution is after dropwising, slowly be warmed up to room temperature, continue reaction 12 hours.After reaction finishes, suction filtration, the DMF in the pressure reducing and steaming filtrate, the resistates acetic acid ethyl dissolution, then use successively distilled water,
Saturated sodium bicarbonate, ethyl acetate layer is collected in saturated common salt washing, the dry post of Sodium Persulfate, filtrate and silica gel mixed sample, evaporate to dryness, solid separates through silicagel column, ethyl acetate and sherwood oil gradient elution, obtain compound (
), structure is as follows:
Wherein X is N-carbobenzoxy-(Cbz)--amino-acid residue.N-carbobenzoxy-(Cbz)-amino acid is preferred following several: N-benzyloxy-oxo-L-valine, N-carbobenzoxy-(Cbz)-D-Val, N-carbobenzoxy-(Cbz)-ILE, N-carbobenzoxy-(Cbz)-L-Phe or N-carbobenzoxy-(Cbz)-L-Trp.
Second step:
10mmol (III) joined in the 100ml ethyl acetate solution, add an amount of 5% palladium carbon (W/W) under the agitation condition and make catalyzer, under the hydrogen condition, carry out catalytic hydrogenation, 40 ° of C reactions of thin layer plate monitoring reaction process 6 hours, after question response is complete, filter, the filtrate decompression evaporate to dryness obtain compound (
-
).
The Decitabine 5 ' of the present invention's preparation-O-amino acid esters prodrug can improve membrane permeability and the oral administration biaavailability of Decitabine preferably.
Description of drawings
Fig. 1 be Decitabine and 5 ' in the rat body-O-amino acid esters prodrug through the time Plasma Concentration figure.
Embodiment
According to above-mentioned general synthetic route, the compound (seeing Table 2) of the embodiment 1-5 that makes respectively.
Embodiment 1:
N-benzyloxy-oxo-L-valine and dicyclohexylcarbodiimide reaction, reaction solvent is anhydrous tetrahydro furan, methylene dichloride or N, the N-4-dimethyl formamide, temperature of reaction is 0 ℃ to 80 ℃, preferred 0 ℃-50 ℃, the reaction times is 1 hour; This reaction solution slowly is added drop-wise to Decitabine and N, in the mixed solution of N-4-dimethyl aminopyridine.Finish, continue reaction 12 hours, temperature is 0 ℃-40 ℃, preferred 10-30 ℃; Reaction solution is cooled to room temperature, the pressure reducing and steaming solvent, resistates is with ethyl acetate or dichloromethane extraction, and successively with distilled water, saturated sodium bicarbonate and saturated common salt washing, collected organic layer, the dry post of Sodium Persulfate, behind the filtrate evaporate to dryness, do under the solvent at ethyl acetate, methylene dichloride or Virahol, add Pd/C and make catalyzer, under the hydrogen condition, carry out catalytic hydrogenation, reaction times is 6 hours, suction filtration, pressure reducing and steaming filtrate, namely get compound (
).
Embodiment 2:
N-carbobenzoxy-(Cbz)-D-Val and dicyclohexylcarbodiimide reaction, reaction solvent is anhydrous tetrahydro furan, methylene dichloride or N, the N-4-dimethyl formamide, temperature of reaction is 0 ℃ to 80 ℃, preferred 0 ℃-50 ℃, the reaction times is 1 hour; This reaction solution slowly is added drop-wise to Decitabine and N, in the mixed solution of N-4-dimethyl aminopyridine.Finish, continue reaction 12 hours, temperature is 0 ℃-40 ℃, preferred 10-30 ℃; Reaction solution is cooled to room temperature, the pressure reducing and steaming solvent, resistates is with ethyl acetate or dichloromethane extraction, and successively with distilled water, saturated sodium bicarbonate and saturated common salt washing, collected organic layer, the dry post of Sodium Persulfate, behind the filtrate evaporate to dryness, do under the solvent at ethyl acetate, methylene dichloride or Virahol, add Pd/C and make catalyzer, under the hydrogen condition, carry out catalytic hydrogenation, reaction times is 6 hours, suction filtration, pressure reducing and steaming filtrate, namely get compound (
).
Embodiment 3:
N-carbobenzoxy-(Cbz)-ILE and dicyclohexylcarbodiimide reaction, reaction solvent is anhydrous tetrahydro furan, methylene dichloride or N, the N-4-dimethyl formamide, temperature of reaction is 0 ℃ to 80 ℃, preferred 0 ℃-50 ℃, the reaction times is 1 hour; This reaction solution slowly is added drop-wise to Decitabine and N, in the mixed solution of N-4-dimethyl aminopyridine.Finish, continue reaction 12 hours, temperature is 0 ℃-40 ℃, preferred 10-30 ℃; Reaction solution is cooled to room temperature, the pressure reducing and steaming solvent, resistates is with ethyl acetate or dichloromethane extraction, and successively with distilled water, saturated sodium bicarbonate and saturated common salt washing, collected organic layer, the dry post of Sodium Persulfate, behind the filtrate evaporate to dryness, do under the solvent at ethyl acetate, methylene dichloride or Virahol, add Pd/C and make catalyzer, under the hydrogen condition, carry out catalytic hydrogenation, reaction times is 6 hours, suction filtration, pressure reducing and steaming filtrate, namely get compound (
).
Embodiment 4:
N-carbobenzoxy-(Cbz)-L-Phe and dicyclohexylcarbodiimide reaction, reaction solvent is anhydrous tetrahydro furan, methylene dichloride or N, the N-4-dimethyl formamide, temperature of reaction is 0 ℃ to 80 ℃, preferred 0 ℃-50 ℃, the reaction times is 1 hour; This reaction solution slowly is added drop-wise to Decitabine and N, in the mixed solution of N-4-dimethyl aminopyridine.Finish, continue reaction 12 hours, temperature is 0 ℃-40 ℃, preferred 10-30 ℃; Reaction solution is cooled to room temperature, the pressure reducing and steaming solvent, resistates is with ethyl acetate or dichloromethane extraction, and successively with distilled water, saturated sodium bicarbonate and saturated common salt washing, collected organic layer, the dry post of Sodium Persulfate, behind the filtrate evaporate to dryness, do under the solvent at ethyl acetate, methylene dichloride or Virahol, add Pd/C and make catalyzer, under the hydrogen condition, carry out catalytic hydrogenation, reaction times is 6 hours, suction filtration, pressure reducing and steaming filtrate, namely get compound (
).
Embodiment 5:
N-carbobenzoxy-(Cbz)-L-Trp and dicyclohexylcarbodiimide reaction, reaction solvent is anhydrous tetrahydro furan, methylene dichloride or N, the N-4-dimethyl formamide, temperature of reaction is 0 ℃ to 80 ℃, preferred 0 ℃-50 ℃, the reaction times is 1 hour; This reaction solution slowly is added drop-wise to Decitabine and N, in the mixed solution of N-4-dimethyl aminopyridine.Finish, continue reaction 12 hours, temperature is 0 ℃-40 ℃, preferred 10-30 ℃; Reaction solution is cooled to room temperature, pressure reducing and steaming solvent, resistates ethyl acetate
Or dichloromethane extraction, and successively with distilled water, saturated sodium bicarbonate and saturated common salt washing, collected organic layer, the dry post of Sodium Persulfate, behind the filtrate evaporate to dryness, do under the solvent at ethyl acetate, methylene dichloride or Virahol, add Pd/C and make catalyzer, under the hydrogen condition, carry out catalytic hydrogenation, reaction times is 6 hours, suction filtration, pressure reducing and steaming filtrate, namely get compound (
).
Example 6:
Utilize rat at body small intestine list Perfusion, choose the long jejunum in rats of 10cm, the two ends intubate. with Decitabine and compound (
)-(
) be dissolved in respectively Kreb-Ringer ' s nutritive medium (pH=5.5), concentration is 0.05mM, with the 0.2mL/min perfusion by jejunum in rats, obtain Decitabine and compound (
)-(
) in the penetrating rate of the film of jejunum.
Embodiment 7:
The research of Sprague-Dawley Rats pharmacokinetics
Give experimental group and control group Sprague-Dawley rat respectively gavage (
) be Decitabine, compound (
) namely 5 '-O-L-valyl Decitabine and compound (
) i.e. 5 '-O-L-phenylalanyl Decitabine (being 15mg/Kg in Decitabine), measure the concentration of Decitabine in the rat plasma.Give simultaneously the Sprague-Dawley rat tail vein injection Decitabine physiological saline aqueous solution (15mg/Kg).Can draw compound by table 1 and Fig. 1
And compound
Compare bioavailability with oral Decitabine and be significantly improved, reached the desired design purpose.
Table 1 respectively oral (
) (
) and Decitabine after, the pharmacokinetic parameters (in Decitabine 15mg/Kg) of Decitabine in the rat body
Claims (5)
1. Decitabine 5 '-O-amino acid esters prodrug, it is characterized in that: 5 ' hydroxyl of Decitabine is by the amino acid esterification, and its general structure is as follows:
Wherein R is amino-acid residue.
2. according to Decitabine 5 ' claimed in claim 1-O-amino acid esters prodrug, it is characterized in that described prodrug is that Decitabine and amino acid are formed by connecting by ester bond, wherein the preferred Valine of R, D-Val, ILE, L-Phe or L-Trp.
3. preparation method such as claim 1 or 2 described Decitabine 5 '-O-amino acid esters prodrug; it is characterized in that: the amino acid Y of Decitabine (II) and carbobenzoxy-(Cbz) protection is at dicyclohexylcarbodiimide and N; under the N-4-dimethyl aminopyridine catalytic condition; become the ester reaction; then slough protecting group through catalytic hydrogenation and form Decitabine 5 '-O-amino acid esters prodrug (I), reaction formula is as follows:
Wherein Y is the amino acid of carbobenzoxy-(Cbz) protection, and X is the amino-acid residue of carbobenzoxy-(Cbz) protection, and R is amino-acid residue.
4. according to preparation method claimed in claim 3, it is characterized in that: the preferred N-benzyloxy-oxo-L-valine of Y, N-carbobenzoxy-(Cbz)-D-Val N-carbobenzoxy-(Cbz)-ILE, N-carbobenzoxy-(Cbz)-L-Phe or N-carbobenzoxy-(Cbz)-L-Trp.
5. the application of claim 1 or 2 described Decitabine 5 '-O-amino acid esters prodrug in preparation treatment myelodysplastic syndrome medicine.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210385724.3A CN102924550B (en) | 2012-10-12 | 2012-10-12 | Decitabine 5'-O-amino-acid ester prodrug and preparation method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210385724.3A CN102924550B (en) | 2012-10-12 | 2012-10-12 | Decitabine 5'-O-amino-acid ester prodrug and preparation method thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102924550A true CN102924550A (en) | 2013-02-13 |
CN102924550B CN102924550B (en) | 2015-02-04 |
Family
ID=47639500
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201210385724.3A Active CN102924550B (en) | 2012-10-12 | 2012-10-12 | Decitabine 5'-O-amino-acid ester prodrug and preparation method thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102924550B (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110746476A (en) * | 2019-01-11 | 2020-02-04 | 江苏豪森药业集团有限公司 | 5-azacytosine nucleoside compound and preparation method thereof |
CN110845560A (en) * | 2019-11-21 | 2020-02-28 | 广东中科药物研究有限公司 | Phenylalanine amidated nucleotide derivative and preparation method and application thereof |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1840538A (en) * | 2005-04-01 | 2006-10-04 | 李伟章 | 1-(2'-deoxy-2'-fluoro-3'-O-amino acid ester-beta-L-furyl arabinosyl)-5-methyl uracil and its application |
US20060241017A1 (en) * | 2003-07-29 | 2006-10-26 | Chandran V R | Novel compounds with high therapeutic index |
CN101812105A (en) * | 2009-02-25 | 2010-08-25 | 沈阳药科大学 | Cytarabine 5'-O-amino-acid ester, salts thereof and preparation method thereof |
-
2012
- 2012-10-12 CN CN201210385724.3A patent/CN102924550B/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060241017A1 (en) * | 2003-07-29 | 2006-10-26 | Chandran V R | Novel compounds with high therapeutic index |
CN1840538A (en) * | 2005-04-01 | 2006-10-04 | 李伟章 | 1-(2'-deoxy-2'-fluoro-3'-O-amino acid ester-beta-L-furyl arabinosyl)-5-methyl uracil and its application |
CN101812105A (en) * | 2009-02-25 | 2010-08-25 | 沈阳药科大学 | Cytarabine 5'-O-amino-acid ester, salts thereof and preparation method thereof |
Non-Patent Citations (2)
Title |
---|
XUEQIN SONG,等: "Amino Acid Ester Prodrugs of the Anticancer Agent Gemcitabine: Synthesis, Bioconversion, Metabolic Bioevasion, and hPEPT1-Mediated Transport", 《MOLECULAR PHARMACEUTICS》, vol. 2, no. 2, 16 March 2005 (2005-03-16), pages 157 - 167, XP009168560 * |
谭昀杜熙,等: "治疗骨髓增生异常综合征新药-地西他滨", 《中国新药杂志》, vol. 19, no. 2, 31 December 2010 (2010-12-31), pages 91 - 94 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110746476A (en) * | 2019-01-11 | 2020-02-04 | 江苏豪森药业集团有限公司 | 5-azacytosine nucleoside compound and preparation method thereof |
CN110845560A (en) * | 2019-11-21 | 2020-02-28 | 广东中科药物研究有限公司 | Phenylalanine amidated nucleotide derivative and preparation method and application thereof |
CN110845560B (en) * | 2019-11-21 | 2021-08-24 | 广东中科药物研究有限公司 | Phenylalanine amidated nucleotide derivative and preparation method and application thereof |
Also Published As
Publication number | Publication date |
---|---|
CN102924550B (en) | 2015-02-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3582784B1 (en) | Processes for the preparation of benzodiazepine derivatives | |
EP2744336A1 (en) | Process and intermediates for preparing macrolactams | |
KR20200086696A (en) | Separation method of benzodiazepin-2-one and benzoazepin-2-one derivatives | |
CN105503739A (en) | Preparation method of high-purity olaparib | |
CN101812105A (en) | Cytarabine 5'-O-amino-acid ester, salts thereof and preparation method thereof | |
CN101250209B (en) | Alexan 5'-O-amino acid ester hydrochloride and preparation method thereof | |
CN101891647A (en) | Preparation method for ubenimex | |
Meltzer et al. | Synthesis and structure–activity relationship of uracil nucleotide derivatives towards the identification of human P2Y6 receptor antagonists | |
CN102924550B (en) | Decitabine 5'-O-amino-acid ester prodrug and preparation method thereof | |
CN106632335A (en) | Preparation method of valaciclovir hydrochloride | |
CN103864885B (en) | The application of 1-hydroxyl-1,2,3-phentriazine-4 (3H)-one in Peptide systhesis | |
CN106928217A (en) | A kind of Analogue of moxifloxacin and preparation method thereof, purposes | |
CN105273023B (en) | A kind of preparation method of 5 '-O-L- valinate hydrochlorides of cytarabine | |
CN109280044B (en) | Raltitrexed impurity C and preparation and application thereof | |
Li et al. | Synthesis and biological evaluation of sophocarpinic acid derivatives as anti-HCV agents | |
CN101580529A (en) | Didanosine pro-medicament and preparation method thereof | |
CN104447763B (en) | Biphenyl tetrazole compound | |
CN103695497B (en) | Enzymatic preparation of naloxone and pharmaceutical composition thereof | |
CN114085221B (en) | Nitrogen-containing heterocyclic compound, marked nitrogen-containing heterocyclic compound, and preparation methods and applications thereof | |
RU2794124C2 (en) | Methods for obtaining benzodiazepine derivatives | |
CN106478625B (en) | A kind of 6 aryl benzo [4,5] imidazo [1,2 a] Carbostyril derivatives and its preparation method and application | |
CN104231008B (en) | The Regioselective synthesis of nucleoside medicine 5 ' bit amino acid esters | |
CN103848816B (en) | The reduction amination method for making of depeptidyl peptidase inhibitors, intermediate and method for making | |
CN117865966A (en) | Carbamate compound, preparation method and medical application thereof | |
CN117964540A (en) | Deuterated pyrrole sulfonyl derivative, and preparation method and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant |